Literature DB >> 26698671

Active surveillance of carbapenem-resistant Enterobacteriaceae in intensive care units: Is it cost-effective in a nonendemic region?

Ka-wai Ho1, Wai-tong Ng1, Margaret Ip2, Joyce H S You3.   

Abstract

OBJECTIVE: Carbapenem-resistant Enterobacteriaceae (CRE) cause significant morbidity and mortality in intensive care unit (ICU) settings. We examined potential cost-effectiveness of active CRE surveillance at ICUs in a nonendemic region from the perspective of a Hong Kong health care provider.
METHODS: A decision analytic model was designed to simulate outcomes of active CRE surveillance in ICUs. Outcome measures included CRE-associated direct medical cost, infection rate, mortality rate, quality-adjusted life year (QALY) loss, and incremental cost per QALY saved by active surveillance. Model inputs were derived from the literature. Sensitivity analyses evaluated the influence of uncertainty of model variables.
RESULTS: In base-case analysis, the surveillance group was more costly ($1,260 vs $1,256) with lower CRE infection rate (5.670% vs 5.902%), CRE-associated mortality rate (2.139% vs 2.455%), and CRE-associated QALY loss (0.3335 vs 0.3827) than the control group. Incremental cost per QALY saved of active surveillance was $81 per QALY saved. One-way sensitivity analyses found base-case results to be robust to a variety of model inputs. In 10,000 Monte Carlo simulations, the surveillance group was the preferred option 99.98% of time.
CONCLUSIONS: Active CRE surveillance in ICUs appears to be highly cost-effective to reduce CRE infection rate, mortality rate, and QALY loss in a low CRE burden region.
Copyright © 2016 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Decision-analytic model; Health technology assessment; Infection control; Multi-drug resistant organisms

Mesh:

Year:  2015        PMID: 26698671     DOI: 10.1016/j.ajic.2015.10.026

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  9 in total

1.  Cost-effectiveness analysis of universal screening for carbapenemase-producing Enterobacteriaceae in hospital inpatients.

Authors:  L Lapointe-Shaw; T Voruganti; P Kohler; H-H Thein; B Sander; A McGeer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-01-11       Impact factor: 3.267

2.  Potential clinical and economic outcomes of active beta-D-glucan surveillance with preemptive therapy for invasive candidiasis at intensive care units: a decision model analysis.

Authors:  Y-K Pang; M Ip; J H S You
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-09-29       Impact factor: 3.267

3.  [External Validation of Carbapenem-Resistant Enterobacteriaceae Acquisition Risk Prediction Model in a Medium Sized Hospital].

Authors:  Su Min Seo; Ihn Sook Jeong
Journal:  J Korean Acad Nurs       Date:  2020-08       Impact factor: 0.984

4.  Trends in Antimicrobial Resistance against Enterobacteriaceae Strains Isolated from Blood: A 10-year Epidemiological Study in Mainland China (2004-2014).

Authors:  Xiang-Jun Liu; Yuan Lyu; Yun Li; Feng Xue; Jian Liu
Journal:  Chin Med J (Engl)       Date:  2017-09-05       Impact factor: 2.628

5.  Emergence of Carbapenemase-Producing Enterobacteriaceae, South-Central Ontario, Canada1.

Authors:  Philipp P Kohler; Roberto G Melano; Samir N Patel; Shumona Shafinaz; Amna Faheem; Brenda L Coleman; Karen Green; Irene Armstrong; Huda Almohri; Sergio Borgia; Emily Borgundvaag; Jennie Johnstone; Kevin Katz; Freda Lam; Matthew P Muller; Jeff Powis; Susan M Poutanen; David Richardson; Anu Rebbapragada; Alicia Sarabia; Andrew Simor; Allison McGeer
Journal:  Emerg Infect Dis       Date:  2018-09       Impact factor: 6.883

6.  Fast and expensive (PCR) or cheap and slow (culture)? A mathematical modelling study to explore screening for carbapenem resistance in UK hospitals.

Authors:  Gwenan M Knight; Eleonora Dyakova; Siddharth Mookerjee; Frances Davies; Eimear T Brannigan; Jonathan A Otter; Alison H Holmes
Journal:  BMC Med       Date:  2018-08-16       Impact factor: 8.775

7.  Prevalence and Risk Factors of Carbapenem-resistant Enterobacteriaceae Acquisition in an Emergency Intensive Care Unit in a Tertiary Hospital in Korea: a Case-Control Study.

Authors:  Jin Suk Kang; Jongyoun Yi; Mee Kyung Ko; Soon Ok Lee; Jeong Eun Lee; Kye Hyung Kim
Journal:  J Korean Med Sci       Date:  2019-05-13       Impact factor: 2.153

8.  A PCR-based diagnostic testing strategy to identify carbapenemase-producing Enterobacteriaceae carriers upon admission to UK hospitals: early economic modelling to assess costs and consequences.

Authors:  Eoin Moloney; Kai Wai Lee; Dawn Craig; A Joy Allen; Sara Graziadio; Michael Power; Carolyn Steeds
Journal:  Diagn Progn Res       Date:  2019-04-18

9.  A Nomogram With Six Variables Is Useful to Predict the Risk of Acquiring Carbapenem-Resistant Microorganism Infection in ICU Patients.

Authors:  Jin Zhang; Wanjun Liu; Wei Shi; Xuanxuan Cui; Yu Liu; Zongqing Lu; Wenyan Xiao; Tianfeng Hua; Min Yang
Journal:  Front Cell Infect Microbiol       Date:  2022-03-25       Impact factor: 5.293

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.